Hippopotamus

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Retrieved on: 
Monday, August 7, 2023
Gilead Sciences, Acquisition, Investment, CVR, Hippopotamus, New Enterprise Associates, IND, Security (finance), Pharmaceutical industry, Bank, Pionýr

BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible preferred stock priced at $7.15 per share.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.
  • “Ikena has made incredible strides this year, and we are glad to welcome the Pionyr shareholders to the Ikena team as we head into a pivotal time for our targeted oncology programs,” said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena.
  • The new Ikena shareholders include New Enterprise Associates, SV Health Investors, Sofinnova Investments, Vida Ventures, and Gilead Sciences.
  • “On behalf of our investors, board of directors, and the Pionyr executive team, I want to thank and congratulate the entire Pionyr team for their efforts.”
    Further details on the transaction are described below.

Hippo Announces Completion of $110M Debut Catastrophe Bond

Retrieved on: 
Thursday, June 1, 2023
Data Management, Residential Building & Real Estate, Technology, Construction & Property, Professional Services, Public Relations, Investor Relations, Communications, Software, Networks, Insurance, Finance, NYSE, MGA, MMC, Fintech, Bookrunner, Reinsurance, Hippopotamus

Spinnaker Insurance Company, a wholly owned subsidiary of Hippo Holdings Inc. (NYSE: HIPO), today announced the successful sponsorship of Mountain Re Ltd. Series 2023-1 catastrophe bond.

Key Points: 
  • Spinnaker Insurance Company, a wholly owned subsidiary of Hippo Holdings Inc. (NYSE: HIPO), today announced the successful sponsorship of Mountain Re Ltd. Series 2023-1 catastrophe bond.
  • The $110 million cat bond is a 10% upsize from the initial $100 million transaction target.
  • “The successful sponsorship of our debut catastrophe bond demonstrates our maturation as a company.
  • It is the direct result of our geographic diversification efforts and will serve as an integral part of our reinsurance program,” said Hippo President and CEO Rick McCathron.

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

Retrieved on: 
Thursday, May 18, 2023
KRAS, Covalent bond, Andrew Bridgen, Therapy, Exception, Cancer, Regenerative medicine, TEAD, Fibrosis, SAN, Drug development, Biology, Hippopotamus, Pharmaceutical industry

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ -- BridGene Biosciences, Inc. , a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled "A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential," at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.

Key Points: 
  • SAN JOSE, Calif., May 18, 2023 /PRNewswire/ -- BridGene Biosciences, Inc. , a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled "A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential," at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.
  • The 2nd Annual Hippo Pathway Targeted Drug Development Summit is an industry-led forum, aimed at accelerating the understanding and opportunity of the Hippo signaling pathway in progressing the discovery, translation, and clinical development of safe and effective therapeutics within oncology, regenerative medicine, fibrosis, and beyond.
  • "Our IMTAC™ live-cell chemoproteomic platform to identify small molecules against challenging targets has successfully identified several potent and drug-like covalent ligands for TEAD and provided the foundation for BridGene to discover its pre-clinical oncology drug candidate BGI-9004," said CEO and Co-founder Ping Cao, Ph.D.
  • Details regarding the poster presentation are as follows:

Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

Retrieved on: 
Tuesday, May 16, 2023
Boston Park Plaza, Drug development, Regenerative medicine, TEAD, Hippopotamus, Tead, Pharmaceutical industry

STOCKHOLM, May 16, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

Key Points: 
  • STOCKHOLM, May 16, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.
  • The conference will take place on May 23-35, 2023, in Boston, Massachusetts.
  • The presentation will showcase a breakthrough in the development of novel cell-active targeted degraders of TEAD, with therapeutic potential against multiple types of life-threatening cancers.
  • The Hippo Pathway Targeted Drug Development Summit is the first and only industry-led forum, uniting a community focused on progressing functional understanding, and realizing the potential of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.

Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

Retrieved on: 
Tuesday, May 16, 2023
Boston Park Plaza, Drug development, Regenerative medicine, TEAD, Hippopotamus, Tead, Pharmaceutical industry

STOCKHOLM, May 16, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

Key Points: 
  • STOCKHOLM, May 16, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.
  • The conference will take place on May 23-35, 2023, in Boston, Massachusetts.
  • The presentation will showcase a breakthrough in the development of novel cell-active targeted degraders of TEAD, with therapeutic potential against multiple types of life-threatening cancers.
  • The Hippo Pathway Targeted Drug Development Summit is the first and only industry-led forum, uniting a community focused on progressing functional understanding, and realizing the potential of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Retrieved on: 
Monday, May 15, 2023
Carcinoma, Insurance, KRAS, AACR, NF2, N-acetyllactosaminide 3-alpha-galactosyltransferase, Quarter, Half-life, Therapeutic index, SOS1, BRAF, Fast Track, Bristol Myers Squibb, Research, MEK, SHP2, AstraZeneca, PI3K, TEAD, Plasma, Patient, Investment, RAS, Data, AHR, FDA, Collaboration, CRAF, IND, Conference, RAF, Vaccine, Pharmaceutical industry, Life insurance, Cryptocurrency, EGFR, Hippopotamus

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date
    BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.
  • “The start to 2023 has been full of exciting developments, including external clinical validation of the Hippo pathway and targeting TEAD.
  • “The first quarter also was the first time we shared the novel profile of IK-595, our MEK-RAF complex inhibitor.
  • Collaboration revenue was $5.3 million and $3.4 million for the three months ended March 31, 2023 and 2022, respectively.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Retrieved on: 
Monday, April 17, 2023
KRAS, AACR, Doctor of Philosophy, Nephrotoxicity, Chromatin, EHE, Therapeutic index, Cancer, American Association for Cancer Research, Toxicity, VGLL4, MEK, TEAD, TEAD1, Beauty, RAS, Patient, EGFR, Mesothelioma, Biology, Hippopotamus, Pharmaceutical industry, Vaccine

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will present preclinical data in two poster presentations highlighting the Company’s novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, FL from April 14-19, 2023.

Key Points: 
  • Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity.
  • Key advantages demonstrated in the nonclinical studies include IK-930’s superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients.
  • IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition.
  • TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma (EHE).

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, News, Rat, AACR, NF2, Therapy, Carcinoma, Neoplasm, MAPK, Cell proliferation, American Association for Cancer Research, Baozou Big News Events, TEAD, TEAD1, Cancer, Mesothelioma, Kidney, Mouse, ADME, TEAD4, TEAD3, RTK, Hippopotamus, TEAD2, IND, Factorization of polynomials, Pharmaceutical industry, Vaccine

“Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

Key Points: 
  • “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
  • SPR1-0117 targets cancers driven by mutations in the Hippo pathway, a key regulator of cell proliferation and oncogenesis not yet extensively targeted in precision oncology.
  • The YAP1/TAZ co-activators and the TEAD family of transcription factors, which consists of four paralogs (TEAD1-4), execute the pro-cancerous effects of the Hippo pathway through transcription of pro-proliferative and anti-apoptotic genes.
  • The published poster is now available in the News & Events section of the Sporos Bioventures website.

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Retrieved on: 
Sunday, April 16, 2023
Molecule, Extremities, Human, AACR, University, NF2, American Association for Cancer Research, Urine, Alanine transaminase, Neoplasm, YAP, Neurofibromatosis, Trial of the century, Mesothelioma, MD Anderson Cancer Center, TEAD, Plasma, Sarcoma, Merlin, Patient, Swelling, SAN, Article, Albuminuria, Nausea, Biology, Pulmonary toxicity, Therapy, Hippopotamus, News, Molecular Cancer Research, Fatigue, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
  • Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
  • Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
  • "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.

Hippo Insurance Selects Opterrix Risk Intelligence Platform to Optimize Claims Workflows

Retrieved on: 
Tuesday, April 11, 2023
Weather, Philosophy, NYSE, GIS, Risk management, Hippopotamus

MADISON, Wis., April 11, 2023 (GLOBE NEWSWIRE) -- Opterrix™, a leader in proactive risk intelligence for the property and casualty insurance industry, today announced that Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, has licensed the Opterrix Claims software and weather data to enhance its claims management capabilities related to extreme weather.

Key Points: 
  • MADISON, Wis., April 11, 2023 (GLOBE NEWSWIRE) -- Opterrix™, a leader in proactive risk intelligence for the property and casualty insurance industry, today announced that Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, has licensed the Opterrix Claims software and weather data to enhance its claims management capabilities related to extreme weather.
  • Opterrix provides Hippo with near real-time awareness of upcoming severe weather events to enhance and expedite their claims response strategies, and street-level analysis tools to better inform post-storm investigation.
  • “Opterrix has built one of the most sophisticated GIS and weather data platforms in the industry,” said Grace Hanson, Chief Claims Officer, and Hippo.
  • Hippo’s focus on the proactive protection of policyholders through the power of real-time insights aligns perfectly with our competitive advantage.”